Argenx SE: Buy rating from DZ Bank

Argenx (ARGX) reported positive Phase 2 data for FB102 in celiac disease and halted its Phase 3 UNITY trial in Sjögren's disease. The stock has fallen 18.5% over 30 days, but long-term returns remain strong. Analysts debate its valuation, with some seeing it as slightly overvalued at €705.60, while a DCF model suggests significant undervaluation at €2,651.18.

H.C. Wainwright reiterated a Buy rating and $1,202 price target for argenx (ARGX) after positive Phase 2 trial results for FB102 in celiac disease. The stock is up 15% premarket. ARGX showed 70% revenue growth over the last year. Analysts have varied price targets and ratings for the company.

Argenx (ARGX) halted its Phase III UNITY trial of efgartigimod SC for Sjögren's disease after an IDMC recommended stopping due to futility. The study failed to meet its primary endpoint, though safety data was consistent. Shares fell 16% to €705.40.

argenx SE (ARGX) stock rose 4.7% to €738.6 after a 15.9% drop due to a failed Phase 3 trial. Analysts maintained positive ratings, citing pipeline resilience and a successful Phase 2 study. The BEL 20 index gained 1.37%, supporting biotech stocks. The stock's 52-week low and discount attracted institutional interest.

Argenx (ARGX) discontinued a Phase 3 trial for Vyvgart in Sjögren's disease after it was unlikely to meet its primary endpoint. The decision caused a 24% drop in shares from their year-to-date high. Despite this, ARGX reported strong Q2 sales of $1.5 billion and positive Phase 2 results for FB102 in celiac disease. Analysts maintain a 'Strong Buy' rating with a mean price target of $1,188.

Analysts lowered argenx SE's average price target from $1201.23 to $1192.11, with a range of $823 to $1450. This implies a 28% upside from the Oct. 7 closing price. The consensus rating remains 'Buy' among 28 analysts, with 24 Buys, 4 Holds, and 0 Sells.